PDGFRa-FIP1L1

FIP1L1-PDGFRA · Variant type: unknown

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ponatinib	100.0%	0.0%	78.23
2	Avapritinib	99.5%	0.5%	97.73
3	Nilotinib	99.1%	0.9%	96.49
4	Tivozanib	98.6%	1.4%	92.42
5	Sorafenib	98.5%	1.4%	96.72
6	Imatinib	98.5%	1.5%	99.00
7	Dasatinib	98.3%	1.6%	87.97
8	Nintedanib	97.4%	2.6%	90.23
9	Regorafenib	97.4%	2.6%	95.99
10	Axitinib	94.8%	5.2%	93.23
11	Erdafitinib	93.4%	6.6%	95.71
12	Cabozantinib	91.2%	8.8%	92.73
13	Lenvatinib	89.8%	10.2%	97.74
14	Selpercatinib	87.6%	12.4%	96.72
15	Sunitinib	80.0%	20.0%	91.73
16	Brigatinib	79.4%	20.6%	82.96
17	Vandetanib	78.7%	21.3%	95.74
18	Ripretinib	77.2%	22.8%	92.95
19	Quizartinib	75.8%	24.2%	99.50
20	Pralsetinib	66.4%	33.6%	93.43
21	Pazopanib	66.3%	33.7%	97.49
22	Vemurafenib	65.2%	34.9%	96.49
23	Alectinib	64.2%	35.8%	95.49
24	Ibrutinib	64.1%	35.9%	94.74
25	Gilteritinib	58.7%	41.3%	88.97

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ponatinib	100.0%	—	—
Avapritinib	99.5%	—	—
Nilotinib	99.1%	—	—
Tivozanib	98.6%	—	—
Sorafenib	98.5%	—	—
Imatinib	98.5%	—	—
Dasatinib	98.3%	—	—
Nintedanib	97.4%	—	—
Regorafenib	97.4%	—	—
Axitinib	94.8%	—	—
Erdafitinib	93.4%	—	—
Cabozantinib	91.2%	—	—
Lenvatinib	89.8%	—	—
Selpercatinib	87.6%	—	—
Sunitinib	80.0%	—	—
Brigatinib	79.4%	—	—
Vandetanib	78.7%	—	—
Ripretinib	77.2%	—	—
Quizartinib	75.8%	—	—
Pralsetinib	66.4%	—	—
Pazopanib	66.3%	—	—
Vemurafenib	65.2%	—	—
Alectinib	64.2%	—	—
Ibrutinib	64.1%	—	—
Gilteritinib	58.7%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.5ms